Capricor Therapeutics, Inc. (CAPR)

Capricor is a clinical-stage biotechnology company with Deramiocel under FDA review (PDUFA target date disclosed as 2026-08-22), making the stock heavily catalyst-driven. SEC filings show strong near-term liquidity (about $237.9M in cash, cash equivalents, and marketable securities as of 2026-06-30, and management states funds are sufficient for at least 12 months), but operating fundamentals are weak: no revenue, large losses, and ongoing cash burn. Traditional valuation multiples are not very informative for a pre-revenue model; the discounted-cash-flow output (~$5.8/share) and analyst consensus target (~$5.83) both sit below the current ~$7.08 price, while key risks include regulatory outcome uncertainty, manufacturing/inspection observations, and legal disputes (including matters tied to Nippon Shinyaku).

The near-term tape is dominated by the regulator-confirmed 2026-08-22 FDA action date for deramiocel, while recent coverage has skewed bearish on the post-AdComm setback/earnings-update framing (last ~14d polarity_score ≈ -0.32). The 30–90d baseline sample was too sparse for a clean sentiment delta, and retail chatter is conspicuously bullish and squeeze-oriented into the decision window; moderate red-flag cap applied due to promotional momentum tone and plaintiff-lawyer solicitation overhang.

CAPR has rebounded off its washout low and reclaimed only the fastest trend proxies, but price is still below the SMA20/EMA21 and far below the SMA50/200 while MACD remains below zero and ADX is under 10; that keeps the chart in bounce-only territory.